Terry L. Ng
University of Ottawa · 112 works · 3,007 citations · h-index 24
Top works
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?
- Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre
- Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion
- Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).
- ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events
- Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer
- Is There a Role for Oral or Intravenous Ascorbate (Vitamin C) in Treating Patients With Cancer? A Systematic Review
- Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials
- Defining optimal control of chemotherapy-induced nausea and vomiting—based on patients’ experience
- Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy
- Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review
- Lung cancer's real adjuvant EGFR targeted therapy questions
- Patients’ considerations of time toxicity when assessing cancer treatments with marginal benefit
- A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting
- Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC
- Patients’ attitudes and preferences toward delayed disease progression in the absence of improved survival
- 2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients
- AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?
- Temozolomide Chronotherapy in Glioma: A Systematic Review